Drug name
Last update: Aug 2026RB0026
Developer(s)
Drug information
RB-0026 ; 库莱韦拜单抗
investigational
Biotherapeutic
Monoclonal antibody - Respiratory syncytial virus F protein inhibitor
RB0026 appears to be a fully human, long-acting anti-RSV monoclonal antibody targeting the RSV F protein, currently being developed by ReYoung (Suzhou) Biology Science & Technology Co., Ltd. for prevention of RSV disease in infants. RB0026's binding targets are likely RSV sites II and IV (compared to site 0 preF for nirsevimab and site IV preF and postF for clesrovimab)
A marketing authorization application has reportedly been accepted by China's NMPA/CDE and granted priority review.
Submitted to NMPA
Therapeutic area(s)
- Respiratory syncytial virus (RSV)
- Prevention
Administration route
Intramuscular
Associated long-acting platforms
Monoclonal antibodies and antibody drug conjugates
Use of drug
- To be determined
- Once
Dosage
to be determined
to be determined
to be determined
Not provided
Not provided
Associated compounds, formulations and regimens
Not provided
Associated technologies
Not provided
Additional information
Developer(s)
ReYoung
ReYoung (Suzhou) Biology Science & Technology Co., Ltd.
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL